Industry Daily Summary
Industry Daily Summary: What Happened on November 4, 2026
Processa buys Vidya, adds $200 million in financing
The deal brings Vidya’s BTK inhibitor pipeline into Processa. GEBRO and Spektus also struck a global pain-drug partnership, while AbbVie invested in a UK expansion.
-
P
Today in brief
Processa acquired Vidya Therapeutics and secured $200 million in PIPE financing for the combined company, with Sheila Gujrathi as executive chair.1 The combined company is developing Vidya’s BTK inhibitor VT-7208 for food allergies, chronic spontaneous urticaria and relapsing multiple sclerosis.1
Processa acquires Vidya and backs the combined company with $200 million
Processa acquired Vidya Therapeutics, with Sheila Gujrathi taking the role of executive chair at the combined company.1 The company has $200 million in PIPE financing and is developing Vidya’s BTK inhibitor VT-7208 for food allergies, chronic spontaneous urticaria and relapsing multiple sclerosis.1
Gujrathi previously served as Receptos’ chief medical officer, co-founded Gossamer Bio and was a co-founding chief financial officer of Prana Therapies.1 Celgene acquired Receptos for $7.2 billion. Bolt Biotherapeutics acquired Prana last month, and Gujrathi became Bolt’s chief strategy officer.1
Also worth knowing
-
GEBRO Holding and Spektus Pharma agreed to commercialize ActraFlex globally. GEBRO will handle Europe and certain other markets, while Spektus will cover Africa, the Americas and Asia through regional partners.2
-
ActraFlex combines paracetamol and tramadol in an extended-release formulation designed for twice-daily use.2
-
P
AbbVie invested £120 million in a UK expansion.3